Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An independent data safety monitoring board has recommended that Genitope continue as planned with its phase III trial of MyVax immunotherapy in non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in Genitope’s pivotal phase III clinical trial in follicular non-Hodgkin’s lymphoma (fNHL) and recommended that the study continue as planned.
This trial is evaluating the safety and efficacy of the company’s lead product candidate, MyVax personalized immunotherapy, in patients with previously untreated fNHL. It compares patients treated with MyVax to patients treated with a non-specific immunotherapy control.
The trial is expected to be completed by December 2007.